Meeting
2019 ASCO Annual Meeting
Second solid (SMN) and hematologic malignant neoplasms (HMN) among 24,900 United States testicular cancer survivors (TCS) after chemotherapy (CHEM), radiotherapy (RT), or surgery only (SURG).
Authors
Mohammad Issam Abu Zaid
Indiana University School of Medicine, Indianapolis, IN
Mohammad Issam Abu Zaid , Michael T. Milano , Paul C Dinh Jr., Sophie Fosså , Hongmei Yang , Darren R. Feldman , Lois B. Travis , Chunkit Fung
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Late and Long-Term Adverse Effects
Citation
J Clin Oncol 37, 2019 (suppl; abstr 11573)
DOI
10.1200/JCO.2019.37.15_suppl.11573
Abstract #
11573
Poster Bd #
265
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Second malignant neoplasms (SMN) among 18,627 testicular cancer survivors (TCS) after chemotherapy (CHEM) or surgery (SURG).
First Author: Chunkit Fung
Poster
2023 ASCO Annual Meeting
Identification and management of clonal hematopoiesis of indeterminate potential (CHIP) in cancer survivors: The Cleveland Clinic experience.
First Author: Teodora Kuzmanovic
Poster
2023 ASCO Genitourinary Cancers Symposium
Impact of chemotherapy on anxiety, depression, and suicidality amongst testicular cancer survivors.
First Author: Tyler J. Nelson
Poster
2022 ASCO Annual Meeting
Cardiovascular disease in testicular cancer survivors: Identification of risk factors and impact on quality of life.
First Author: Sjoukje Lubberts